Related Experiment Video
Updated: Sep 17, 2025

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
Published on: August 31, 2015
PknB and STP as potential targets of luteolin in combating Trueperella pyogenes infections
Yueting Guo1, Hongyu Su1, Lihui Yu1
1Key Laboratory of Livestock Infectious Diseases, Ministry of Education, and Key Laboratory of Ruminant Infectious Disease Prevention and Control (East), Ministry of Agriculture and Rural Affairs, College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, 120 Dongling Road, Shenyang, 110866, China.
Abstract:
Trueperella pyogenes (T. pyogenes) is a significant opportunistic pathogen that causes suppurative infection in many animals, as well as humans. Considering the strong drug resistance of T. pyogenes, the development of novel antibacterial drugs and drug targets to combat infections is necessary. Serine/threonine protein kinases (STKs) and serine/threonine phosphatases (STPs) play pivotal roles in the physiological processes, pathogenesis, and resistance of several important bacterial pathogens, indicating their potential as antimicrobial drug targets. In this study, we aimed to investigate the effects of luteolin, a natural flavonoid, on serine/threonine protein kinase B (PknB) and serine/threonine phosphatase (STP). The results revealed that after T. pyogenes was treated with 1/2 MIC (39 μg/mL) luteolin for 36 h, the transcription and translation levels of the pknB and stp genes decreased significantly. Molecular docking revealed that hydrophobic forces were predominant in the interaction between luteolin and PknB, whereas hydrogen bonding was predominant in the interaction between luteolin and STP. The results of the molecular interaction assay revealed that the KD value of luteolin with PknB and STP were 3.125 × 10-4 M and 1.128 × 10-5 M, respectively. Additionally, luteolin could inhibit the activities of PknB and STP. Our study demonstrated that luteolin can inhibit PknB and STP at multiple levels, and it is expected to be used as a PknB/STP inhibitor to develop new drugs against drug-resistant bacterial infections.

